MARKET

SGMT

SGMT

Sagimet Biosciences Inc.
NASDAQ
10.83
+0.98
+9.95%
After Hours: 10.62 -0.21 -1.94% 19:30 11/09 EST
OPEN
9.95
PREV CLOSE
9.85
HIGH
10.86
LOW
9.70
VOLUME
1.09M
TURNOVER
--
52 WEEK HIGH
11.45
52 WEEK LOW
4.500
MARKET CAP
763.87M
P/E (TTM)
-8.4504
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at SGMT last week (1026-1030)?
Weekly Report · 11/02 10:19
Weekly Report: what happened at SGMT last week (1019-1023)?
Weekly Report · 10/26 10:19
Sagimet Biosciences Inc. Announces Clinical Updates for Denifanstat and TVB-3567
NASDAQ · 10/22 15:12
Sagimet Biosciences Begins Pivotal Phase 3 Study Of Denifanstat In Acne Patients
NASDAQ · 10/22 15:07
Sagimet announces dosing of first patient in AURORA study
TipRanks · 10/22 14:46
H.C. Wainwright views Sagimet dosing news as ‘incrementally positive’
TipRanks · 10/22 14:45
Sagimet Maintains Buy Rating as Phase 3 AURORA Trial Advances and $28 Price Target Remains Unchanged
TipRanks · 10/22 14:45
Analysts Offer Insights on Healthcare Companies: Sagimet Biosciences, Inc. Class A (SGMT) and Revolution Medicines (RVMD)
TipRanks · 10/22 12:50
More
About SGMT
Sagimet Biosciences Inc. is a clinical-stage biopharmaceutical company developing fatty acid synthase (FASN) inhibitors that are designed to target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. The Company's lead drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction associated steatohepatitis (MASH). Denifanstat has been granted Breakthrough Therapy designation by the FDA for the treatment of non-cirrhotic MASH with moderate to advanced liver fibrosis. The Company is also exploring the use of its FASN inhibitors, which include denifanstat and its pipeline product candidate, TVB-3567, in acne and in select forms of cancer. Denifanstat is being tested in China by its license partner, Ascletis BioScience Co. Ltd., for moderate to severe acne vulgaris and recurrent glioblastoma multiforme in combination with bevacizumab.

Webull offers Sagimet Biosciences Inc stock information, including NASDAQ: SGMT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SGMT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SGMT stock methods without spending real money on the virtual paper trading platform.